147 related articles for article (PubMed ID: 15864807)
1. The truth about activated clotting time measurements.
Bittl JA
Catheter Cardiovasc Interv; 2005 Jul; 65(3):338-9. PubMed ID: 15864807
[No Abstract] [Full Text] [Related]
2. Research review: use of activated clotting time to monitor heparin therapy in coronary patients.
Noureddine SN
Am J Crit Care; 1995 Jul; 4(4):272-7; quiz 278-9. PubMed ID: 7663590
[TBL] [Abstract][Full Text] [Related]
3. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
4. Clinical safety and cost of heparin titration using bedside activated clotting time.
Thomason T; Riegel B; Jessen D; Smith SC; Gocka I; Rich M
Am J Crit Care; 1993 Jan; 2(1):81-7. PubMed ID: 8353584
[TBL] [Abstract][Full Text] [Related]
5. [Prescription and monitoring of anticoagulant therapies].
Laviolle B; Oger E
Rev Prat; 2008 Nov; 58(18):2063-70. PubMed ID: 19143281
[No Abstract] [Full Text] [Related]
6. Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA): assessment of three bedside coagulation monitors.
Hézard N; Metz D; Potron G; Nazeyrollas P; Maes D; Droulle C; Mulpas MC; Elaerts J; Nguyen P
Thromb Haemost; 1998 Nov; 80(5):865-6. PubMed ID: 9843190
[No Abstract] [Full Text] [Related]
7. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory.
Doherty TM; Shavelle RM; French WJ
Catheter Cardiovasc Interv; 2005 Jul; 65(3):330-7. PubMed ID: 15864806
[TBL] [Abstract][Full Text] [Related]
8. When we "act" on ACT levels: activated clotting time measurements to guide heparin administration during and after interventional procedures.
Klein LW; Agarwal JB
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):154-7. PubMed ID: 8808071
[TBL] [Abstract][Full Text] [Related]
9. Optimal activated clotting time during percutaneous coronary intervention.
Hanratty CG; Ward M
Circulation; 2001 Oct; 104(15):E83-4. PubMed ID: 11591634
[No Abstract] [Full Text] [Related]
10. [Measurement of activated clotting time during cardiopulmonary bypass in infective endocarditis patients].
Jiang L; Yu JF
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):167-9. PubMed ID: 17344611
[TBL] [Abstract][Full Text] [Related]
11. Management of prekallikrein deficiency during cardiac surgery.
Eeckhoudt SL; Momeni M; Matta A; Latinne D; Arnout J; Hermans C
Thromb Haemost; 2010 Apr; 103(4):866-7. PubMed ID: 20135073
[No Abstract] [Full Text] [Related]
12. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
13. Advantages for the use of the activated clotting time (ACT).
Pesola DA; Pesola HR; Pesola GR
Am J Crit Care; 1995 Sep; 4(5):414-5. PubMed ID: 7489050
[No Abstract] [Full Text] [Related]
14. Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.
Bowers J; Ferguson JJ
Tex Heart Inst J; 1993; 20(4):258-63. PubMed ID: 8298321
[TBL] [Abstract][Full Text] [Related]
15. Defining the optimal activated clotting times during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
Helft G; Beygui F; le Feuvre C; Metzger JP
Circulation; 2001 Nov; 104(22):E124. PubMed ID: 11723037
[No Abstract] [Full Text] [Related]
16. Anticoagulation monitoring.
Ng VL
Clin Lab Med; 2009 Jun; 29(2):283-304. PubMed ID: 19665679
[TBL] [Abstract][Full Text] [Related]
17. Heparinase-modified thrombelastometry: inactivation of heparin in plasma samples.
Cvirn G; Tafeit E; Hoerl G; Janschitz M; Wagner T; Juergens G; Koestenberger M
Clin Lab; 2010; 56(11-12):585-9. PubMed ID: 21141445
[TBL] [Abstract][Full Text] [Related]
18. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin).
Toulon P; Ajzenberg N; Smahi M; Guillin MC
Thromb Res; 2007; 119(2):135-43. PubMed ID: 16426667
[TBL] [Abstract][Full Text] [Related]
19. The use of activated clotting times to monitor heparin therapy during and after interventional procedures.
Bowers J; Ferguson JJ
Clin Cardiol; 1994 Jul; 17(7):357-61. PubMed ID: 8088021
[TBL] [Abstract][Full Text] [Related]
20. A functional clotting assay to monitor the hirudin dosage.
Zakir RM; Hoffman W; Bhatt BA; Spillert CR
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):119-23. PubMed ID: 17287627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
